Aurinia pharmaceuticals inc. AUPH.US Overview
BetaUS StockHealthcare
(No presentation for AUPH)
AUPH AI Analysis & Strategy
Analysis Conclusion
The stock has been awarded the top rating for its value, but its dividend score is below 2. If the company starts distributing dividends, it may yield even better investment results.
AUPH Current Performance
-1.89%
Aurinia pharmaceuticals inc.
-0.35%
Avg of Sector
-0.22%
S&P500
AUPH Key Information
AUPH Financial Forecast
Unit : USD
AUPH Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | 0.16 | 633.3% | 100% | 62.47M | 24.2% | -3.4% | 2.4% |
| 2024Q3 | 0.09 | 147.4% | 200% | 59.87M | 32.8% | -3.2% | 21.2% |
| 2024Q2 | 0.1 | 211.1% | 566.7% | 67.77M | 24.3% | 4.2% | 1.3% |
| 2024Q1 | 0.02 | 125% | 20% | 57.19M | 37.8% | 3.9% | -21.4% |
| 2023Q4 | -0.03 | 83.3% | -82.4% | 50.3M | 46.2% | 6% | -59.6% |
AUPH Profile
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.